These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 28279470)

  • 1. Novel Targeted Therapies for Esophagogastric Cancer.
    Maron SB; Catenacci DV
    Surg Oncol Clin N Am; 2017 Apr; 26(2):293-312. PubMed ID: 28279470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
    Maron SB; Catenacci DVT
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
    Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
    Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
    Pant S; Patel M; Kurkjian C; Hemphill B; Flores M; Thompson D; Bendell J
    Cancer Invest; 2017 Aug; 35(7):463-472. PubMed ID: 28662341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
    Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
    J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
    Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
    Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.
    Wang WP; Wang KN; Gao Q; Chen LQ
    World J Surg Oncol; 2012 Jan; 10():14. PubMed ID: 22252115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
    Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L
    Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
    Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
    Roviello G; Petrioli R; Marano L; Polom K; Marrelli D; Perrella A; Roviello F
    Gastric Cancer; 2016 Jan; 19(1):31-41. PubMed ID: 26329368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.
    Hjortland GO; Meza-Zepeda LA; Beiske K; Ree AH; Tveito S; Hoifodt H; Bohler PJ; Hole KH; Myklebost O; Fodstad O; Smeland S; Hovig E
    BMC Cancer; 2011 Oct; 11():455. PubMed ID: 22014070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
    Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
    J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma.
    Yoon HH; Lewis MA; Foster NR; Sukov WR; Khan M; Sattler CA; Wiktor AE; Wu TT; Jenkins RB; Sinicrope FA
    Int J Cancer; 2016 Oct; 139(7):1626-31. PubMed ID: 27198655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
    Joshi SS; Maron SB; Catenacci DV
    Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies.
    Kim S; Barzi A; Rajdev L
    Semin Oncol; 2018 Jun; 45(3):133-150. PubMed ID: 30262395
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
    Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
    Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
    J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
    Pasini F; Fraccon AP; Modena Y; Bencivenga M; Giacopuzzi S; La Russa F; Gusella M; de Manzoni G
    Gastric Cancer; 2017 Jan; 20(1):31-42. PubMed ID: 27568322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.